Generic
Azilsartan Medoxomil
Description
Adarbi 80 is an antihypertensive medication containing Azilsartan Medoxomil, used to effectively manage high blood pressure (hypertension) and reduce the risks of cardiovascular complications. It works by relaxing blood vessels, allowing smoother blood flow and reducing strain on the heart.
Benefits
Adarbi 80 lowers blood pressure and reduces the risk of heart disease, heart attack, and stroke. It can also help protect kidney function, particularly in patients with diabetes. Taken daily, it ensures long-term cardiovascular protection and improved health outcomes.
Ingredients
Active Ingredient: Azilsartan Medoxomil 80 mg.
Inactive Ingredients: May include fillers, binding agents, and stabilizers as specified by the manufacturer.
Uses and Doses
Adarbi 80 is prescribed for hypertension and heart failure. Adults typically start with a dose of 40 mg, which may be increased to 80 mg as required. Taken once daily, with or without food, at the same time each day for best results.
Side Effects
Common side effects include dizziness, diarrhea, and muscle spasms. Less frequently, nausea, fatigue, and postural hypotension may occur. Notify a healthcare provider if any side effects persist or worsen.
How to Use
Take Adarbi 80 exactly as prescribed by your doctor. Swallow the tablet whole, without crushing or chewing. It may be taken with or without food, though consistency in timing is recommended for optimal efficacy.
Pregnancy & Lactation
Adarbi 80 is categorized as Pregnancy Category D, posing risks to fetal health if used in the second or third trimesters. Breastfeeding mothers should consult a doctor, as its excretion in breast milk is unknown and may impact the infant.
Precautions and Warnings
Caution is advised for patients with renal or hepatic impairments. Patients with a history of volume depletion should be monitored for hypotension. Potassium levels may need monitoring, particularly in those taking potassium-sparing diuretics or supplements. Avoid use during pregnancy and lactation without medical advice.
Safety Information
Regular monitoring of kidney function, blood pressure, and potassium levels is recommended for patients on Adarbi 80. Avoid NSAIDs as they may reduce the antihypertensive effect and increase the risk of kidney issues.
Indications
Adarbi 80 is indicated for hypertension treatment, either alone or in combination with other antihypertensive agents, aiming to reduce cardiovascular event risks like heart attack and stroke.
Pharmacology
Azilsartan Medoxomil, a prodrug, converts to Azilsartan upon absorption. It is a selective angiotensin II receptor blocker (ARB), targeting AT1 receptors and reducing blood pressure through vasodilation.
Therapeutic Class
Angiotensin II Receptor Blockers (ARB)
Storage Conditions
Store in a cool, dry place away from light and heat. Keep out of the reach of children.
3 FAQ
- What if I miss a dose?
Skip the missed dose and continue as scheduled. Do not double the dose. - Can Adarbi 80 cause dizziness?
Yes, some patients experience dizziness, especially during the initial days of treatment. - Is it safe for breastfeeding mothers?
Consult a doctor, as it’s unclear if Adarbi 80 passes into breast milk.
Disclaimer
This information is provided for educational purposes and is not a substitute for professional medical advice. Always consult a healthcare provider for any questions about medications.
Keywords: Azilsartan Medoxomil, hypertension treatment, high blood pressure, Adarbi 80, Nipro JMI Pharma, angiotensin receptor blocker, cardiovascular health, blood pressure medication, antihypertensive, kidney protection, stroke prevention, heart attack prevention, ARB class, hypertension medication, heart failure treatment, blood pressure control, health management, medicine for hypertension, diabetic kidney health, heart protection
Additional information
Weight | 0.02 kg |
---|---|
Dimensions | 4.5 × 2 × 0.3 in |
Class -Dosage | Tablets |
Size | 80mg |
Generics | Azilsartan Medoxomil |
pharmaceuticals | Nipro JMI Pharma Ltd |
Reviews
There are no reviews yet.